JP2013503903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013503903A5 JP2013503903A5 JP2012528089A JP2012528089A JP2013503903A5 JP 2013503903 A5 JP2013503903 A5 JP 2013503903A5 JP 2012528089 A JP2012528089 A JP 2012528089A JP 2012528089 A JP2012528089 A JP 2012528089A JP 2013503903 A5 JP2013503903 A5 JP 2013503903A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- hydrogen
- independently selected
- alkoxyalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 4
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 3
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims 2
- HNVIQLPOGUDBSU-UHFFFAOYSA-N 2,6-dimethylmorpholine Chemical compound CC1CNCC(C)O1 HNVIQLPOGUDBSU-UHFFFAOYSA-N 0.000 claims 2
- UYGRGONQGJGYDY-UHFFFAOYSA-N 2-fluoropiperidine Chemical compound FC1CCCCN1 UYGRGONQGJGYDY-UHFFFAOYSA-N 0.000 claims 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims 2
- -1 C 1 -C 5 alkoxy Chemical group 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 2
- OTWVFHZMWFGHSJ-UHFFFAOYSA-N 1-fluoropyrrolidine Chemical compound FN1CCCC1 OTWVFHZMWFGHSJ-UHFFFAOYSA-N 0.000 claims 1
- OQDXZZHGQBFAKM-UHFFFAOYSA-N 2-fluoropyrrolidine Chemical compound FC1CCCN1 OQDXZZHGQBFAKM-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 201000010183 Papilledema Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010038886 Retinal oedema Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000005243 carbonyl alkyl group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 201000010206 cystoid macular edema Diseases 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 239000003885 eye ointment Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000011195 retinal edema Diseases 0.000 claims 1
- 208000032253 retinal ischemia Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 150000003871 sulfonates Chemical class 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23960309P | 2009-09-03 | 2009-09-03 | |
| US61/239,603 | 2009-09-03 | ||
| US30661610P | 2010-02-22 | 2010-02-22 | |
| US61/306,616 | 2010-02-22 | ||
| US35669910P | 2010-06-21 | 2010-06-21 | |
| US61/356,699 | 2010-06-21 | ||
| US36053110P | 2010-07-01 | 2010-07-01 | |
| US61/360,531 | 2010-07-01 | ||
| PCT/US2010/047816 WO2011029001A1 (en) | 2009-09-03 | 2010-09-03 | Compounds as tyrosine kinase modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013503903A JP2013503903A (ja) | 2013-02-04 |
| JP2013503903A5 true JP2013503903A5 (https=) | 2013-10-24 |
Family
ID=43086186
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528089A Pending JP2013503903A (ja) | 2009-09-03 | 2010-09-03 | チロシンキナーゼモジュレーターとしての化合物 |
| JP2012528084A Expired - Fee Related JP5868855B2 (ja) | 2009-09-03 | 2010-09-03 | チロシンキナーゼ調節剤としての化合物 |
| JP2016001387A Expired - Fee Related JP6109974B2 (ja) | 2009-09-03 | 2016-01-06 | チロシンキナーゼ調節剤としての化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528084A Expired - Fee Related JP5868855B2 (ja) | 2009-09-03 | 2010-09-03 | チロシンキナーゼ調節剤としての化合物 |
| JP2016001387A Expired - Fee Related JP6109974B2 (ja) | 2009-09-03 | 2016-01-06 | チロシンキナーゼ調節剤としての化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US8809534B2 (https=) |
| EP (2) | EP2473513B1 (https=) |
| JP (3) | JP2013503903A (https=) |
| KR (2) | KR20120047313A (https=) |
| CN (2) | CN102686577A (https=) |
| AU (2) | AU2010289359A1 (https=) |
| BR (2) | BR112012004718A2 (https=) |
| CA (2) | CA2772625A1 (https=) |
| CL (2) | CL2012000587A1 (https=) |
| ES (1) | ES2730086T3 (https=) |
| IL (2) | IL218332A0 (https=) |
| IN (1) | IN2012DN02493A (https=) |
| MX (2) | MX2012002591A (https=) |
| NZ (2) | NZ598781A (https=) |
| PH (1) | PH12014500281A1 (https=) |
| RU (2) | RU2012112151A (https=) |
| SG (2) | SG178963A1 (https=) |
| WO (2) | WO2011028995A1 (https=) |
| ZA (2) | ZA201201592B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| CN102131801B (zh) | 2008-06-25 | 2015-04-08 | 福拉姆医药股份有限公司 | 1,2-二取代的杂环化合物 |
| EP2340244A4 (en) | 2008-10-14 | 2012-07-25 | Ning Xi | COMPOUNDS AND APPLICATION PROCEDURES |
| ES2578990T3 (es) | 2009-03-21 | 2016-08-03 | Sunshine Lake Pharma Co., Ltd. | Derivados de amino éster, sales de los mismos y métodos de uso |
| KR101662699B1 (ko) | 2009-05-07 | 2016-10-05 | 포럼 파마슈티칼즈 인크. | 페녹시메틸 헤테로고리 화합물 |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| CA3186189A1 (en) | 2009-05-18 | 2010-11-25 | Dose Medical Corporation | Drug eluting ocular implant |
| IN2012DN02493A (https=) * | 2009-09-03 | 2015-08-28 | Allergan Inc | |
| US8906944B2 (en) * | 2009-09-03 | 2014-12-09 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US9668915B2 (en) | 2010-11-24 | 2017-06-06 | Dose Medical Corporation | Drug eluting ocular implant |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| HRP20161578T1 (hr) * | 2012-02-09 | 2016-12-30 | Merck Patent Gmbh | Derivati furo[3, 2-b]piridina kao inhibitori tbk1 i ikk |
| WO2015069287A1 (en) * | 2013-11-08 | 2015-05-14 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US9856223B2 (en) | 2013-12-13 | 2018-01-02 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| EP3079682A4 (en) | 2013-12-13 | 2017-08-30 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| CN104974132B (zh) * | 2014-04-08 | 2017-05-17 | 北大方正集团有限公司 | 多取代的吡啶化合物、制备方法、用途及药物组合物 |
| EP3677229A1 (en) | 2014-05-29 | 2020-07-08 | Glaukos Corporation | Implants with controlled drug delivery features |
| KR102431436B1 (ko) | 2014-08-29 | 2022-08-10 | 테스 파마 에스.알.엘. | α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제 |
| CN104326985A (zh) * | 2014-09-24 | 2015-02-04 | 安润医药科技（苏州）有限公司 | 利你法尼的制备方法 |
| US10112957B2 (en) | 2014-10-22 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| CN107531679B (zh) * | 2016-03-18 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 芳香酰胺类衍生物、其制备方法及其在医药上的应用 |
| EP3442479B1 (en) | 2016-04-20 | 2026-03-04 | Glaukos Corporation | Bioresorbable ocular drug delivery device |
| CN107663202B (zh) * | 2016-07-29 | 2020-09-04 | 西华大学 | 3-(脲基-甲基)-4-芳基-吡啶衍生物及其制备方法和作为抗肝癌药物的应用 |
| JP7086987B2 (ja) | 2017-03-21 | 2022-06-20 | ザ スクリプス リサーチ インスティテュート | 銅およびニッケル触媒による脱炭酸ホウ素化反応 |
| PE20191817A1 (es) | 2017-05-11 | 2019-12-27 | Bristol Myers Squibb Co | Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4) |
| CN110770210A (zh) * | 2017-05-18 | 2020-02-07 | Pi工业有限公司 | 新颖的脒化合物 |
| JP7640458B2 (ja) | 2018-10-05 | 2025-03-05 | アンナプルナ バイオ インコーポレイテッド | Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物 |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US4966849A (en) * | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
| US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| DE69105495T2 (de) | 1990-04-02 | 1995-04-06 | Pfizer | Benzylphosphonsäure-tyrosinkinaseinhibitoren. |
| US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| US5409930A (en) | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| EP0586608A1 (en) | 1991-05-29 | 1994-03-16 | Pfizer Inc. | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
| WO1994003427A1 (en) | 1992-08-06 | 1994-02-17 | Warner-Lambert Company | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
| US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| WO1999020617A1 (en) * | 1997-10-21 | 1999-04-29 | Active Biotech Ab | Antiinflammatory thiadiazolyl ureas which act as lfa-1 and mac-1 inhibitors |
| DE60137273D1 (de) * | 2000-10-20 | 2009-02-12 | Eisai R&D Man Co Ltd | Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten |
| MXPA03010099A (es) * | 2001-05-08 | 2004-03-10 | Schering Ag | Amidas de antranilamida-piridina selectivas como inhibidores de vegfr-2 y vegfr-3. |
| CA2461812C (en) * | 2001-09-27 | 2011-09-20 | Allergan, Inc. | 3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors |
| US6541504B1 (en) * | 2002-04-03 | 2003-04-01 | Allergan Sales, Llc | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
| TWI319387B (en) * | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| UA77303C2 (en) * | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
| US20050058689A1 (en) | 2003-07-03 | 2005-03-17 | Reactive Surfaces, Ltd. | Antifungal paints and coatings |
| US6747025B1 (en) | 2002-11-27 | 2004-06-08 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
| GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
| EP1603879A2 (en) * | 2003-02-28 | 2005-12-14 | Bayer Pharmaceuticals Corporation | Substituted pyridine derivatives useful in the treatment of cancer and other disorders |
| WO2004113274A2 (en) * | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| EP1660504B1 (en) * | 2003-08-29 | 2008-10-29 | Pfizer Inc. | Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents |
| EP1660503A1 (en) * | 2003-08-29 | 2006-05-31 | Pfizer Inc. | Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents |
| EP1753428A4 (en) * | 2004-05-14 | 2010-09-15 | Abbott Lab | INHIBITORS OF KINASES AS THERAPEUTIC AGENTS |
| UY29300A1 (es) * | 2004-12-22 | 2006-07-31 | Astrazeneca Ab | Compuestos quimicos |
| PL1848435T3 (pl) | 2005-01-25 | 2016-08-31 | Synta Pharmaceuticals Corp | Związki przeciwko zapaleniom i zastosowania związane z odpornością |
| TWI444187B (zh) * | 2005-01-25 | 2014-07-11 | Synta Pharmaceuticals Corp | 用於炎症及免疫相關用途之噻吩化合物 |
| ES2400287T3 (es) | 2005-03-14 | 2013-04-08 | High Point Pharmaceuticals, Llc | Derivados de benzazol, composiciones y procedimientos de uso como inhibidores de beta-secretasa |
| JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| AU2006313456B2 (en) * | 2005-05-20 | 2011-06-23 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
| CA2610509A1 (en) * | 2005-06-03 | 2006-12-14 | Bayer Healthcare Ag | 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents |
| DE102005062742A1 (de) * | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
| US20070155746A1 (en) * | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| JP2009526761A (ja) * | 2006-01-30 | 2009-07-23 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環式チオフェン化合物および使用の方法 |
| WO2007107005A1 (en) * | 2006-03-22 | 2007-09-27 | Methylgene, Inc. | Inhibitors of protein tyrosine kinase activity |
| ES2336625T3 (es) * | 2006-03-22 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos. |
| US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| KR20100014811A (ko) * | 2007-04-20 | 2010-02-11 | 데시페라 파마슈티칼스, 엘엘씨. | 골수증식성 질환 및 기타 증식성 질환의 치료에 유용한 키나제 억제제 |
| BRPI0810719A8 (pt) * | 2007-04-30 | 2016-03-08 | Abbott Lab | Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1 |
| US8907091B2 (en) * | 2007-08-29 | 2014-12-09 | Methylgene Inc. | Processes and intermediates for preparing fused heterocyclic kinase inhibitors |
| BRPI0816064B8 (pt) * | 2007-08-29 | 2021-05-25 | Methylgene Inc | composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica |
| US20090118276A1 (en) * | 2007-11-02 | 2009-05-07 | Wyeth | Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors |
| WO2009070328A1 (en) | 2007-11-26 | 2009-06-04 | The Regents Of The University Of California | Modulators of the epidermal growth factor receptor (egfr) pathway for use in the treatment or prevention of substance abuse |
| US20100324086A1 (en) * | 2008-02-19 | 2010-12-23 | Novasaid Ab | Compounds and methods |
| BRPI0908573A2 (pt) | 2008-03-05 | 2012-12-25 | Methylgene Inc | inibidores da atividade de proteÍna tirosina quinase |
| WO2010036629A2 (en) * | 2008-09-26 | 2010-04-01 | National Health Research Institutes | Fused multicyclic compounds as protein kinase inhibitors |
| IN2012DN02493A (https=) | 2009-09-03 | 2015-08-28 | Allergan Inc | |
| US8906944B2 (en) * | 2009-09-03 | 2014-12-09 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
-
2010
- 2010-09-03 IN IN2493DEN2012 patent/IN2012DN02493A/en unknown
- 2010-09-03 BR BR112012004718A patent/BR112012004718A2/pt not_active IP Right Cessation
- 2010-09-03 ES ES10760159T patent/ES2730086T3/es active Active
- 2010-09-03 MX MX2012002591A patent/MX2012002591A/es not_active Application Discontinuation
- 2010-09-03 US US12/875,223 patent/US8809534B2/en active Active
- 2010-09-03 CN CN2010800482682A patent/CN102686577A/zh active Pending
- 2010-09-03 BR BR112012004843A patent/BR112012004843A2/pt not_active IP Right Cessation
- 2010-09-03 WO PCT/US2010/047800 patent/WO2011028995A1/en not_active Ceased
- 2010-09-03 CA CA2772625A patent/CA2772625A1/en not_active Abandoned
- 2010-09-03 MX MX2012002596A patent/MX2012002596A/es not_active Application Discontinuation
- 2010-09-03 JP JP2012528089A patent/JP2013503903A/ja active Pending
- 2010-09-03 NZ NZ598781A patent/NZ598781A/en not_active IP Right Cessation
- 2010-09-03 RU RU2012112151/04A patent/RU2012112151A/ru not_active Application Discontinuation
- 2010-09-03 WO PCT/US2010/047816 patent/WO2011029001A1/en not_active Ceased
- 2010-09-03 AU AU2010289359A patent/AU2010289359A1/en not_active Abandoned
- 2010-09-03 EP EP10752975.2A patent/EP2473513B1/en not_active Not-in-force
- 2010-09-03 CA CA2772718A patent/CA2772718C/en active Active
- 2010-09-03 US US12/875,218 patent/US8614234B2/en active Active
- 2010-09-03 SG SG2012015038A patent/SG178963A1/en unknown
- 2010-09-03 AU AU2010289353A patent/AU2010289353B2/en not_active Ceased
- 2010-09-03 RU RU2012109233/04A patent/RU2012109233A/ru not_active Application Discontinuation
- 2010-09-03 EP EP10760159.3A patent/EP2473501B1/en not_active Not-in-force
- 2010-09-03 JP JP2012528084A patent/JP5868855B2/ja not_active Expired - Fee Related
- 2010-09-03 KR KR1020127008527A patent/KR20120047313A/ko not_active Withdrawn
- 2010-09-03 CN CN2010800389522A patent/CN102498114A/zh active Pending
- 2010-09-03 NZ NZ598455A patent/NZ598455A/en not_active IP Right Cessation
- 2010-09-03 KR KR1020127008525A patent/KR20120082890A/ko not_active Withdrawn
- 2010-09-03 SG SG2012015053A patent/SG178965A1/en unknown
-
2012
- 2012-02-27 IL IL218332A patent/IL218332A0/en unknown
- 2012-02-28 IL IL218374A patent/IL218374A0/en unknown
- 2012-03-02 CL CL2012000587A patent/CL2012000587A1/es unknown
- 2012-03-02 CL CL2012000592A patent/CL2012000592A1/es unknown
- 2012-03-02 ZA ZA2012/01592A patent/ZA201201592B/en unknown
- 2012-03-05 ZA ZA2012/01627A patent/ZA201201627B/en unknown
-
2013
- 2013-10-15 US US14/054,444 patent/US9328103B2/en active Active
-
2014
- 2014-02-03 PH PH12014500281A patent/PH12014500281A1/en unknown
-
2015
- 2015-07-08 US US14/793,913 patent/US9475801B2/en active Active
-
2016
- 2016-01-06 JP JP2016001387A patent/JP6109974B2/ja not_active Expired - Fee Related
- 2016-09-19 US US15/269,612 patent/US9725433B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013503903A5 (https=) | ||
| RU2012109233A (ru) | Соединения как модуляторы тирозинкиназы | |
| RU2483072C2 (ru) | Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12 | |
| CA2917735C (en) | Protein tyrosine kinase modulators and methods of use | |
| RU2704129C2 (ru) | Соединение 2-аминопиримидина и фармацевтическая композиция и применение данного соединения | |
| AU2016299485B2 (en) | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same | |
| TWI586649B (zh) | ６－乙炔基吡啶及其用途 | |
| KR102122244B1 (ko) | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 | |
| TWI619717B (zh) | 三唑并吡 | |
| TW202140461A (zh) | Ras抑制劑及其使用方法 | |
| US20150238601A1 (en) | Treatment of ocular disorders | |
| BRPI0924126A2 (pt) | composto heterocíclico bicíclico | |
| RU2013153529A (ru) | Новые соединения и композиции для ингибирования nampt | |
| EA200601350A1 (ru) | Азотсодержащие гетероциклические производные и их фармацевтические применения | |
| WO2005007651A1 (ja) | ２-アシルアミノチアゾール誘導体又はその塩 | |
| RU2010145463A (ru) | Производные замещенного 2-фенилпиридина | |
| MXPA05010816A (es) | Derivados de 4-(4- (heterociclilalcox}fenil)- 1-(heterociclil- carbonil) piperidina y compuestos relacionados como antagonistas de h3 de la histamina para el tratamiento de enfermedades neurologicas tales como alzheimer. | |
| JP2026020169A (ja) | Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤 | |
| CA2730471A1 (en) | Piperazine derivatives used as cav2.2 calcium channel modulators | |
| WO2024153240A1 (zh) | 一种杂环化合物及其制备方法和应用 | |
| IL292466B1 (en) | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(adp-ribose) polymerase-1-related diseases, comprising the same as active ingredient | |
| JP7080346B2 (ja) | 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホノアミダート | |
| JP2020535172A (ja) | Ｓｒｐｋ１阻害剤 | |
| RU2008127264A (ru) | Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза | |
| CA3213396A1 (en) | Compositions and methods for treating anemia associated with a ribosomal disorder |